Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
The hirsute woman: Challenges in evaluation and management
Rodis Paparodis
,
Andrea Dunaif
Research output
:
Contribution to journal
›
Review article
›
peer-review
27
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The hirsute woman: Challenges in evaluation and management'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Hirsutism
100%
Women Challenges
100%
Oral Contraceptives
36%
Testosterone
27%
Spironolactone
18%
Metformin
18%
Etiology
9%
United States
9%
Polycystic Ovary Syndrome
9%
Androgen Receptor
9%
Postmenopausal Women
9%
Treatment Options
9%
Monotherapy
9%
Clinical Course
9%
Clinical Problems
9%
Alternative Therapy
9%
17-hydroxyprogesterone (17-OHP)
9%
Diagnostic Management
9%
Prolactin
9%
Total Testosterone
9%
Sex Hormone-binding Globulin
9%
Androgen-independent
9%
Thyrotropin
9%
Dehydroepiandrosterone Sulfate (DHEAS)
9%
Active Metabolite
9%
Finasteride
9%
Diagnostic Approach
9%
Teratogenicity
9%
Dihydrotestosterone
9%
Hair Growth
9%
Metformin Use
9%
Antiandrogen
9%
Early Morning
9%
Terminal Hair
9%
Follicular Phase
9%
Flutamide
9%
Androgen Action
9%
Reductase Activity
9%
Cyproterone Acetate
9%
Phase Measurement
9%
Pilosebaceous Unit
9%
Medicine and Dentistry
Hirsutism
100%
Glycon
27%
Oral Contraceptive Agent
27%
Androgen
18%
Physical Examination
18%
Spironolactone
18%
Monotherapy
9%
Laboratory Test
9%
Polycystic Ovary Syndrome
9%
Androgen Receptor
9%
Disease Course
9%
Oxidoreductase
9%
Hydroxyprogesterone
9%
Oral Contraceptive
9%
Premenopause
9%
Sex Hormone Binding Globulin
9%
Glucocorticoid
9%
Thyrotropin
9%
Bioavailability
9%
Prolactin
9%
Pilus
9%
Teratogenicity
9%
Prasterone Sulfate
9%
Disease
9%
Androstanolone
9%
Target Tissue
9%
Antiandrogen
9%
Flutamide
9%
Follicular Phase
9%
Cyproterone Acetate
9%
Active Metabolite
9%
Treatment Option
9%
Pharmacology, Toxicology and Pharmaceutical Science
Hirsutism
100%
Oral Contraceptive Agent
27%
Metformin
27%
Androgen
18%
Spironolactone
18%
Monotherapy
9%
Ovary Polycystic Disease
9%
Androgen Receptor
9%
Glucocorticoid
9%
Disease Course
9%
Thyrotropin
9%
Bioavailability
9%
Hydroxyprogesterone
9%
Active Metabolite
9%
Dehydroepiandrosterone Sulfate
9%
Teratogenicity
9%
Androstanolone
9%
Prolactin
9%
Oxidoreductase
9%
Antiandrogen
9%
Finasteride
9%
Oral Contraceptive
9%
Flutamide
9%
Cyproterone Acetate
9%
Sex Hormone Binding Globulin
9%